Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Pharmacology, Toxicology and Pharmaceutical Science
Therapeutic Drug Monitoring
100%
Ganciclovir
66%
Posaconazole
66%
Infection
63%
Prospective Study
40%
Molecular Epidemiology
33%
Placebo
33%
Cmin
33%
Mucosa Inflammation
33%
Neutropenia
33%
Inflammation
33%
Human Parainfluenza Virus 3
33%
Anakinra
33%
Antiinfective Agent
33%
Cytomegalovirus
30%
Adverse Event
16%
Melphalan
12%
C Reactive Protein
11%
Sialidase
11%
Antifungal Agent
11%
Immunocompromised Patient
11%
Hemagglutinin
11%
Thymoma
11%
HIV
11%
Multiple Myeloma
9%
Observational Study
9%
Antivirus Agent
8%
Systemic Mycosis
8%
Opportunistic Infection
8%
Randomized Controlled Trial
8%
Haemophilus Influenzae Type B Vaccine
8%
Interleukin 1
6%
Chemotherapy
6%
Therapeutic Window
5%
Metapneumovirus
5%
Mycosis
5%
Keyphrases
Mucositis
33%
Neutropenia
33%
Fever
33%
Therapeutic Drug Monitoring
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Ganciclovir
33%
Randomized Placebo-controlled Trial
33%
Anakinra
33%
Bordetella Bronchiseptica
33%
Bovine Parainfluenza Virus Type 3 (BPIV3)
33%
Respiratory Viruses
33%
Respiratory Viral Infection
33%
Patients with Hematological Malignancies
33%
Community-acquired
33%
Fixed-dose Regimen
33%
Optimized Dosing Regimen
33%
Cytomegalovirus
22%
High-dose Melphalan
14%
Load Estimation
11%
HIV Patients
11%
Immunocompromised Patients
11%
Viral Load
11%
Heart Transplant Recipients
11%
Thymoma
11%
Multiple Myeloma
11%
Hemagglutinin-neuraminidase Gene
11%
ICU Admission
11%
Parainfluenza
11%
Virus
11%
Hospitalization
11%
Hematopoietic Stem Cell Transplant Recipients
9%
Risk Factors
9%
Interleukin-1β
7%
Hematopoietic Stem Cell Transplantation
7%
Liver Function Markers
6%
Characteristic Risk
5%
Metapneumovirus
5%
Influenza
5%
Secondary Bacterial Infection
5%
Future Community
5%
Improved Patient Outcomes
5%
Early Diagnosis
5%
High Morbidity
5%
Targeted Therapy
5%
COVID-19
5%
Lymphopenia
5%
Smoking History
5%
Risk Outcomes
5%
Severe Outcomes
5%
Overall Mortality
5%
Immunology and Microbiology
Trough Concentration
66%
Respiratory Virus
37%
Zoonotic
33%
Bordetella bronchiseptica
33%
Transplant Procedure
33%
Viral Disease
33%
Vaccine Efficacy
33%
Human Parainfluenza Virus 3
33%
Drug Exposure
33%
Molecular Epidemiology
33%
Breakthrough Infection
33%
C-Reactive Protein
33%
Arm
16%
Drug Dose Reduction
16%
Opportunistic Infection
16%
Stem Cell Transplant
16%
Embase
16%
Cytomegalovirus
16%
Hib Vaccine
16%
Hemagglutinin-Neuraminidase
11%
Attenuated Vaccine
11%
Live Vaccine
11%
Awareness
11%
Vaccination Policy
11%
Body Weight
6%
Antifungal Activity
6%
Mortality Rate
5%
Virus
5%
Influenza
5%
Respiratory Syncytial Virus
5%
Parainfluenza
5%
Lymphocytopenia
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Paramyxovirinae
5%
Metapneumovirus
5%
